REGN vs ROP · P/E 14, rev $14.34B vs P/E 41, rev $1.88B
Regeneron Pharmaceuticals Inc (REGN) versus Roper Technologies, Inc. (ROP) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Roper Technologies, Inc. (ROP) is a software - application company listed on US.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported ROP revenue for 2024-12-31 was $1.88B. Net income was $462.3M. Revenue was up 6.4% from 2024-09-30 to 2024-12-31. ROP currently screens at market cap $61.61B and trailing P/E 41.3.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. ROP currently screens at market cap $61.61B and trailing P/E 41.3.
Not investment advice. Open the REGN and ROP stock pages for the full models.
Not investment advice.